We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Boundless Bio Inc | NASDAQ:BOLD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.56 | 5.99% | 9.91 | 9.88 | 10.00 | 10.06 | 9.26 | 9.47 | 44,122 | 18:15:56 |
Delaware
|
|
46-1606174
|
(State or other jurisdiction of
|
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification Number)
|
Effie Toshav, Esq.
Robert A. Freedman, Esq.
Amanda L. Rose, Esq.
Fenwick & West LLP 1191 Second Avenue
Seattle, WA 98101
(206) 389-4510 |
Large accelerated filer
|
|
x
|
|
Accelerated filer
|
|
o
|
Non-accelerated filer
|
|
o
|
|
Smaller reporting company
|
|
o
|
|
|
|
|
Emerging growth company
|
|
o
|
|
|
|
|
|
Title of Each Class of Securities
to be Registered
|
Amount to be
Registered
(1)
|
Proposed Maximum
Offering Price
Per Unit
|
Proposed Maximum
Aggregate Offering
Price
|
Amount of
Registration
Fee
|
Common Stock, $0.00001 par value
|
|
|
|
|
- To be issued under the 2016 Equity Incentive Plan
|
2,177,339
(2)
|
$37.15
(3)
|
$80,888,144
|
$9,804
|
- To be issued under the 2016 Employee Stock Purchase Plan
|
435,467
(4)
|
$31.58
(5)
|
$13,752,048
|
$1,667
|
TOTAL
|
2,612,806
|
N/A
|
$94,640,192
|
$11,471
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “
Securities Act
”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Registrant’s 2016 Equity Incentive Plan (the “
2016
EIP
”) and 2016 Employee Stock Purchase Plan (the “
2016 ESPP
”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of common stock.
|
(2)
|
Represents additional shares of common stock reserved for issuance under the Registrant’s 2016 EIP as of January 1, 2019.
|
(3)
|
Calculated solely for the purposes of this offering under Rules 457(c) and (h) of the Securities Act based on the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on May 8, 2019.
|
(4)
|
Represents additional shares of common stock reserved for issuance under the 2016 ESPP Plan as of January 1, 2019
|
(5)
|
Calculated solely for the purposes of this offering under Rules 457(c) and (h) of the Securities Act based on the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on May 8, 2019, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2016 ESPP.
|
|
(a)
|
the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Commission on March 1, 2019, pursuant to Section 13 of the Exchange Act;
|
|
(b)
|
all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and
|
|
(b)
|
the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001- 37833) filed on July 13, 2016 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.
|
Exhibit
|
|
|
|
Incorporated by Reference
|
|
Filed
|
||||||
Number
|
|
Exhibit Description
|
|
Form
|
|
File No.
|
|
Exhibit
|
|
Filing Date
|
|
Herewith
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4.1
|
|
|
S-1
|
|
333-208842
|
|
3.2
|
|
7/11/2016
|
|
|
|
4.2
|
|
|
S-1
|
|
333-208842
|
|
3.4
|
|
7/11/2016
|
|
|
|
4.4
|
|
|
S-1
|
|
333-208842
|
|
4.1
|
|
3/9/2016
|
|
|
|
5.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
24.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
99.1
|
|
|
S-1
|
|
333-208842
|
|
10.3
|
|
7/11/2016
|
|
|
|
99.2
|
|
|
S-1
|
|
333-208842
|
|
10.4
|
|
7/11/2016
|
|
|
AUDENTES THERAPEUTICS, INC.
|
|
|
||
|
|
|
||
By:
|
|
/s/ Matthew R. Patterson
|
||
|
|
Matthew R. Patterson
|
||
|
|
Chief Executive Officer
|
|
Signature
|
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
|
/s/ Matthew R. Patterson
|
|
|
Chief Executive Officer and Chairman
(Principal Executive Officer
|
|
May 10, 2019
|
|
Matthew R. Patterson
|
|
|
|
||
|
|
|
|
|
|
|
|
/s/ Thomas Soloway
|
|
|
Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)
|
|
May 10, 2019
|
|
Thomas Soloway
|
|
|
|
||
|
|
|
|
|
|
|
|
/s/ Mark Goldberg
|
|
|
Director
|
|
May 10, 2019
|
|
Mark Goldberg
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Jennifer Jarrett
|
|
|
Director
|
|
May 10, 2019
|
|
Jennifer Jarrett
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Louis Lange
|
|
|
Director
|
|
May 10, 2019
|
|
Louis Lange
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Scott Morrison
|
|
|
Director
|
|
May 10, 2019
|
|
Scott Morrison
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Thomas Schuetz
|
|
|
Director
|
|
May 10, 2019
|
|
Thomas Schuetz
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Julie Smith
|
|
|
Director
|
|
May 10, 2019
|
|
Julie Smith
|
|
|
|
|
|
1 Year Boundless Bio Chart |
1 Month Boundless Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions